The purpose of this study is to determine whether functional genetic variants can affect tacrolimus dose corrected trough levels and associate with the side effects in Chinese renal transplantation and liver transplantation.
Description: time to acute rejection
Measure: Kidney transplant recipient genotypes Time: Day 0 to Day 30Description: time to Calcineurin Inhibitor (CNI)-related nephrotoxicities
Measure: Kidney transplant recipient genotypes Time: Day 0 to Day 30Description: time to Calcineurin Inhibitor (CNI)-related neurotoxicities
Measure: Kidney transplant recipient genotypes Time: Day 0 to Day 30Description: time to acute rejection
Measure: Liver transplant recipient genotypes Time: Day 0 to Day 30Description: time to Calcineurin Inhibitor (CNI)-related nephrotoxicities
Measure: Liver transplant recipient genotypes Time: Day 0 to Day 30Description: time to Calcineurin Inhibitor (CNI)-related neurotoxicities
Measure: Liver transplant recipient genotypes Time: Day 0 to Day 30Description: time to acute rejection
Measure: Liver donor genotypes Time: Day 0 to Day 30Description: time to Calcineurin Inhibitor (CNI)-related nephrotoxicities
Measure: Liver donor genotypes Time: Day 0 to Day 30Description: time to Calcineurin Inhibitor (CNI)-related neurotoxicities
Measure: Liver donor genotypes Time: Day 0 to Day 30Cohort
There is one SNP
Full understanding of this mechanism is important for the personalized use of tacrolimus and reducing the risk of side effects.The CYP3A5*3 (A6986G) resulting in a splicing defect and the absence of protein activity, was identified as a functional variant (Kuehl P.2001). --- A6986G ---